Mega Fine Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.53 Cr
- Company Age 29 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 48.00 Cr
- Satisfied Charges ₹ 48.75 Cr
- Revenue Growth 7.00%
- Profit Growth -7.66%
- Ebitda -10.91%
- Net Worth 15.36%
- Total Assets 7.43%
About Mega Fine Pharma
Mega Fine Pharma Private Limited (MFPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 22 August 1995 and has a history of 29 years and six months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.53 Cr.
The company currently has active open charges totaling ₹48.00 Cr. The company has closed loans amounting to ₹48.75 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ashok Jhaveri, Shailesh Sanghvi, and Hasmukh Gandhi serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24239MH1995PTC092028
- Company No.
092028
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Aug 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Mega Fine Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shailesh Sanghvi  | Whole-Time Director | 22-Aug-1995 | Current |
| Ashok Jhaveri | Director | 05-Jun-2024 | Current |
| Hasmukh Gandhi | Whole-Time Director | 14-Apr-2000 | Current |
Financial Performance of Mega Fine Pharma.
Mega Fine Pharma Private Limited, for the financial year ended 2024, experienced modest growth in revenue, with a 7% increase. The company also saw a slight decrease in profitability, with a 7.66% decrease in profit. The company's net worth Soared by an impressive increase of 15.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mega Fine Pharma?
In 2024, Mega Fine Pharma had a promoter holding of 49.24% and a public holding of 50.76%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Fhh Healthcare International Private LimitedAshok Jhaveri is a mutual person
- Aar Cube Enterprise Llp
Shailesh Sanghvi is a mutual person
- Jms Venture Llp
Shailesh Sanghvi is a mutual person
Charges (Loans)
₹48.00 Cr
₹48.75 Cr
Charges Breakdown by Lending Institutions
- State Bank Of India : 39.50 Cr
- Hdfc Bank Limited : 8.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Apr 2012 | Hdfc Bank Limited | ₹8.50 Cr | Open |
| 13 Jun 2006 | State Bank Of India | ₹39.50 Cr | Open |
| 22 Nov 2019 | Hdfc Bank Limited | ₹44.50 Cr | Satisfied |
| 29 Sep 2003 | Canara Bank | ₹2.70 Cr | Satisfied |
| 05 Jun 2002 | Canara Bank | ₹0.80 M | Satisfied |
How Many Employees Work at Mega Fine Pharma?
Mega Fine Pharma has a workforce of 758 employees as of Dec 12, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mega Fine Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mega Fine Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
